Berlin Cures: BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.